What is the recommended dosing, administration, and monitoring for a lignocaine infusion in acute ventricular tachycardia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Lignocaine Infusion in Ventricular Tachycardia

For hemodynamically stable monomorphic VT, administer lignocaine (lidocaine) as an initial bolus of 1-1.5 mg/kg IV, followed by a maintenance infusion of 1-4 mg/min (typically 2 mg/min), with a maximum cumulative dose of 3 mg/kg. 1

Clinical Context and Drug Selection

Lignocaine is now considered a second-line agent for stable monomorphic VT in modern guidelines. The 2010 AHA guidelines classify it as a "relatively weak sodium channel blocker" and recommend procainamide or amiodarone as first-line options 1. However, lignocaine remains particularly useful when VT is associated with acute myocardial ischemia or infarction 2.

The evidence base shows lignocaine is significantly less effective than alternatives:

  • Procainamide is 3.7 times more likely to terminate VT than lignocaine 3
  • Ajmaline is 5.3 times more effective 3
  • Sotalol is 3.9 times more effective 3

Dosing Algorithm

Initial Loading Dose

  • 1-1.5 mg/kg IV bolus over 2-3 minutes 1
  • For cardiac arrest: 100 mg bolus, repeatable after 5-10 minutes 4
  • For stable VT with adverse signs: 50 mg over 2 minutes, repeated every 5 minutes to maximum total of 200 mg 4

Maintenance Infusion

  • Standard rate: 2 mg/min after successful cardioversion 4
  • Range: 1-4 mg/min (30-50 mcg/kg/min) 1
  • Optimal rate for heart failure patients: 1 mg/min (achieves 78.6% probability of therapeutic levels) 5

Maximum Dosing Limits

  • Maximum cumulative bolus dose: 3 mg/kg 1
  • Without epinephrine: 4.5 mg/kg or 300 mg total 6
  • With epinephrine: 7 mg/kg or 500 mg total 6

Critical Monitoring Requirements

Therapeutic Drug Monitoring

  • Target plasma concentration: 1.5-5.0 μg/L 5
  • Steady-state achieved in 3-4 hours in normal patients 7
  • In myocardial infarction: 8-10 hours to steady state 7
  • In heart failure: may take 24-48 hours, with continued rise in levels 7

Clinical Monitoring

Monitor continuously for:

  • CNS toxicity (earliest signs): paresthesia, drowsiness, slurred speech, altered consciousness, muscular twitching, seizures 4, 6
  • Cardiovascular effects: bradycardia, hypotension, myocardial depression 1
  • Respiratory adequacy 6

Special Populations and Dose Adjustments

Heart Failure Patients

  • Reduce maintenance infusion to 1 mg/min 5
  • Decreased clearance and volume of distribution require lower loading and maintenance doses 7
  • Plasma levels may continue rising for 24-48 hours 7

Hepatic Disease

  • Use with extreme caution - lignocaine is metabolized exclusively by the liver 6, 7
  • Reduced clearance necessitates dose reduction 7
  • Lignocaine clearance is a sensitive marker of hepatic dysfunction 7

Elderly and Debilitated Patients

  • Reduce both loading and maintenance doses 6

Common Pitfalls and Contraindications

Avoid Lignocaine When:

  • Wide-QRS tachycardia of unknown origin - use procainamide instead 2
  • Polymorphic VT with prolonged QT (torsades de pointes) - use magnesium instead 1
  • No effect on supraventricular tachycardia - completely ineffective 4

Critical Timing Issue

The subtherapeutic gap problem: Traditional bolus-then-infusion creates a dangerous drop in plasma levels between peak bolus concentration and steady-state infusion levels 8. This gap allows breakthrough arrhythmias. Consider using a continuous infusion at 25 mg/min with weight-based dosing to eliminate this hiatus 8.

Response Assessment

In chronic VPBs, do not assess response before 8 hours - the antiarrhythmic effect is significantly delayed compared to acute-onset VPBs, where response occurs within the first hour 9. Making premature decisions about efficacy leads to inappropriate drug changes.

Drug Interactions

  • Avoid with MAO inhibitors or tricyclic antidepressants if epinephrine is co-administered (risk of severe hypertension) 6
  • Beta-blockers may mask tachycardia from accidental intravascular injection 6

Administration Technique

  • Always flush with 20 mL saline after peripheral IV administration to ensure central circulation delivery 4
  • Avoid rapid bolus injection - administer over 2-3 minutes to minimize toxicity risk
  • For refractory or recurrent VT, consider electrical cardioversion or transvenous pacing rather than escalating lignocaine doses 2

References

Guideline

pharmacological treatment of significant cardiac arrhythmias.

British Journal of Sports Medicine, 2000

Research

Clinical pharmacokinetics of lignocaine.

Clinical pharmacokinetics, 1978

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.